



### Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.7809 mL	8.9044 mL	17.8088 mL
5 mM	0.3562 mL	1.7809 mL	3.5618 mL
10 mM	0.1781 mL	0.8904 mL	1.7809 mL
50 mM	0.0356 mL	0.1781 mL	0.3562 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Saenz d T I, et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil[J]. International Journal of Impotence Research, 2001, 13(5):282.

Prickaerts J, et al. Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic GMP levels in the rat[J]. Neuroscience, 2002, 113(2):351-361.

Blount M A, et al. Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation[J]. Molecular Pharmacology, 2004, 66(1):144-152.

Ferrini M G, et al. Vardenafil prevents fibrosis and loss of corporal smooth muscle that occurs after bilateral cavernosal nerve resection in the rat[J]. Urology, 2006, 68(2):429-435.

Salloum F N, et al. Sildenafil and Vardenafil but not Nitroglycerin Limit Myocardial Infarction through Opening of Mitochondrial KATP Channels when Administered at Reperfusion following Ischemia in Rabbits[J]. Journal of Molecular & Cellular Cardiology, 2007, 42(2):453-458.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481